Tactical HOLD at benchmark weight with disciplined dual-gate ADD triggers and defined downside exit
HOLD at benchmark weight captures the 2.97% dividend carry and structural floor while the setup resolves. Do not add at current levels ($146 with 200 SMA as current price, only $0.66 margin of safety). Do not trim at current levels. Reject aggressive ADD until dual confirmation gates clear. Reject conservative UNDERWEIGHT as structural franchise floor (30% ROE, 70-year dividend streak, A+ credit, $15B FCF) remains intact; UNDERWEIGHT thesis has failed in 4 of 5 recent windows. Tactical trim zone at $148.50–$150.00 exists only for portfolio rebalancing, never as directional view.
| Position | Action |
|---|---|
| Current levels (~$145) | Maintain at benchmark weight within consumer staples allocation |
| Rally into $148.50–$150.00 confluence zone (50 SMA/Bollinger upper band/swing high) | Tactical trim only if portfolio rebalancing requires it |
| 200 SMA breaks decisively: close <$145 with rising ATR (>3.37) AND negative MACD histogram | Reduce to UNDERWEIGHT, 25–50% position cut |
| Price <$145.87 (200 SMA, failed support) | Never trim — that is capitulation, not rebalancing |
PG's ~20% pullback from 2024 highs, combined with the unpriced Thorne wellness acquisition, fortress balance sheet, and 70-year dividend streak, creates a compelling entry point where fundamentals, technicals, and macro tailwinds align to favor buying over holding.
| Indicator | Value | Signal |
|---|---|---|
| Close | 145.21 | neutral |
| close_10_ema | 146.25 | bearish |
| close_50_sma | 146.80 | bearish |
| close_200_sma | 145.87 | neutral |
| RSI(14) | 46.13 | neutral |
| MACD | −0.32 | bearish |
| MACD Histogram | −0.14 | bearish |
| Bollinger Upper | 150.22 | neutral |
| Bollinger Middle | 146.94 | neutral |
| Bollinger Lower | 143.66 | neutral |
| ATR(14) | 3.37 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Q1 FY27 organic growth >2% with gross margin ≥50.18%
Then: ADD triggers activated (fundamental leg complete)
PG's balance sheet and capital efficiency metrics represent an essentially irreplaceable competitive moat that generates reliable shareholder returns through any cycle.
↩ rebuts: “Bear's 'margin compression in Q4' framing misses that a 230 bps compression is a manageable quarterly blip for a franchise this strong, not a structural break.”
· concedes: Bear correctly identifies one quarter of margin compression (230 bps in Q4 FY26) — though the bull characterizes this as cyclical, not structural; Bear's PEG of 4.2 metric, while critiqued as wrong framework, does indicate elevated valuation relative to growth rate on that specific metric; Recent stock underperformance (1-year TSR -2.73%) is factual — though bull argues this creates the entry opportunity rather than being a negative signal; FY27 guidance of +1-3% organic is at the low end of ranges — conservative guidance is acknowledged, framed as management style rather than concern; Tariff risk is real and unresolved — bull acknowledges this while arguing PG has demonstrated manageability through similar historical shocks; Bear's technical observation of price below moving averages, while disputed on the 200 SMA framing, does reflect recent relative weakness
The bull's "coiled spring" thesis is dangerously wrong—PG has lost support at the 200 SMA, faces a two-year margin compression trend that pricing power cannot reverse, overpaid $3.8B for Thorne at exactly the wrong moment, and trades at a 21.94 P/E that prices in perfection for a deteriorating business with 1-3% organic growth guidance and a $1B unresolved cost headwind.
→ vs conservative: Conservative analyst is 'pattern-matching to a broken chart' and missing that $19.56B operating cash flow up 9.8% proves pricing power through tariff headwinds
→ vs conservative: Conservative analyst 'waves away' franchise quality metrics including 30.29% ROE, negative working capital, and fortress balance sheet that warrant higher valuation
→ vs conservative: Conservative analyst ignores that 1-3% FY27 organic sales guidance came AFTER absorbing $1B cost headwind and demonstrates managed cycle, not deterioration
→ vs neutral: Neutral analyst's 'wait for confirmation' logic is 'paralysis dressed up as risk management'—waiting for MACD confirmation means buying after the move has already occurred
→ vs neutral: Neutral analyst treats Thorne acquisition as 'mixed' but the $3.8B deal is a strategic pivot from pure-play defensive to defensive-plus-health-growth compounders
→ vs neutral: Neutral analyst's 'balanced debate' framing is 'intellectually tidy but operationally limp'—stop at $143 is essentially at the bottom of the range, making position too small to matter
→ vs neutral: HOLD is not a hedge against hot CPI either—PG goes down on hot print with or without the position, and goes up on soft print capturing nothing if holding back
| bearish |
Support: 143.66 · 144.49 · 139 · 140 | Resistance: 145.87 · 146.25 · 146.8 · 146.94 · 148.88 · 150.22
PG is range-bound between 139–152 with a mild bearish drift; price at 145.21 is below the 10 EMA (146.25), 50 SMA (146.80), and essentially at the 200 SMA (145.87). Momentum is bearish (MACD −0.32, histogram −0.14), RSI is neutral at 46.13, and ATR has risen 14% to 3.37. Five bearish signals stack up but the 200 SMA at 145.87 has been defended multiple times since May 2026, with the Bollinger lower band at 143.66 and range floor at 139–140 providing cushions. The recommended action is HOLD existing positions; wait for a close above 146.80 with positive MACD for longs, or a break below 143.66 with rising histogram for shorts.
Market Cap
$337.53B
PE Ratio (TTM)
21.94
Forward PE
19.62
PEG Ratio
4.20
Price/Book
6.33
Dividend Yield
2.97%
Beta
0.377
EPS (TTM)
$6.62
Forward EPS
$7.40
Revenue FY2026
$87.03B
Revenue FY2025
$84.28B
Revenue FY2024
$84.04B
Revenue FY2023
$82.01B
Revenue CAGR FY23-FY26
~2.0%
Gross Margin FY2026
50.18%
Operating Income FY2026
$19.75B
Net Income FY2026
$16.05B
Diluted EPS FY2026
$6.62
Diluted EPS FY2025
$6.51
Diluted EPS FY2024
$6.02
Diluted EPS FY2023
$5.90
EPS CAGR FY23-FY26
~3.9%
Net Income CAGR FY23-FY26
~3.1%
Q4 FY2026 Operating Margin
~18.6%
Q4 FY2026 Revenue
$21.20B
Q4 FY2026 Operating Income
$3.95B
Q4 FY2026 EPS
$1.26
Total Assets
$126.52B
Total Debt
$35.03B
Total Equity
$54.31B
Net Debt
$24.20B
Debt/Equity
64.5%
Current Ratio
0.68
Cash & Equivalents
$9.94B
Goodwill & Intangibles
$62.72B
Retained Earnings
$135.9B
Operating Cash Flow FY2026
$19.56B
Capital Expenditure FY2026
$4.41B
Free Cash Flow FY2026
$15.15B
Dividends Paid FY2026
$10.23B
Share Repurchases FY2026
$5.03B
FCF Per Share (TTM)
~$6.10
Total Shareholder Returns FY2026
~$15.26B
Gross Margin
50.9%
Operating Margin
22.7%
Net Margin
18.4%
ROE
30.29%
ROA
10.72%
EBITDA
$24.75B
EBITDA Margin
28.4%
52-Week Range
$137.62 – $167.25
50-Day MA
$147.58
200-Day MA
$147.94
Implied Price (TTM)
~$145.20
Strengths
Concerns
PG exhibits all hallmarks of a best-in-class defensive franchise — elite 30.29% ROE, 67+ year dividend aristocrat status, fortress balance sheet ($126.5B assets, $24.2B net debt), and high-quality cash earnings ($19.56B OCF, $15.15B FCF). However, the stock is fairly-to-modestly expensively valued (PEG 4.2), recent operating margin compression in Q4 FY26 (-230 bps YoY to ~18.6%) is a yellow flag, and organic growth remains modest (~2-3%). With price range-bound around moving averages and no clear near-term catalyst, risk/reward is balanced. Capital return model is textbook: ~$15.26B returned to shareholders (95% of FCF) through dividends and buybacks. Watch Q1 FY27 earnings for confirmation on whether Q4 margin pressure was transitory or structural.
Macro: Soft-landing base case priced at 8% US recession odds (down −2pp WoW); Japan 32%, UK 18%. Risk-off but non-recessionary environment rotating toward quality/defensives. July CPI release is the dominant near-term catalyst with binary implications for Treasury yields and defensive-sector relative performance. Yen intervention wearing off maintains USD strength pressure (translation tailwind, import-cost headwind). Crude oil tail risk re-emerges on Hormuz deal doubts. Tariff regime unresolved — flagged as single biggest FY27 earnings drag with incomplete pass-through to consumers.